NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9800
-0.0900 (-4.35%)
At close: 4:00PM EDT

1.9900 +0.01 (0.51%)
After hours: 7:55PM EDT

Stock chart is not supported by your current browser
Previous Close2.0700
Open2.0700
Bid1.9900 x 3100
Ask1.9800 x 3200
Day's Range1.9500 - 2.0701
52 Week Range1.1200 - 3.2700
Volume2,174,965
Avg. Volume1,107,610
Market Cap147.194M
Beta (3Y Monthly)2.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. iBio (NYSE: IBIO ) shares were down 14% to ...

  • Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
    Zacks

    Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

    Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

  • Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
    Zacks

    Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta

    The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

  • FDA Nods Fuel Unusual Options Volume on NBRV, MRNA
    Schaeffer's Investment Research

    FDA Nods Fuel Unusual Options Volume on NBRV, MRNA

    Call options are running much hotter than usual today

  • Benzinga

    Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential

    The  FDA approved Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV )'s lead antibiotic asset, Xenleta, on Monday for the treatment of community-acquired bacterial infections.  The Analysts Bank of America ...

  • Benzinga

    Nabriva Shares Rip Higher Following FDA Nod For Novel Antibiotic

    Nabriava, a thinly-traded micro-cap biotech, announced late Monday the FDA approved its NDA for the oral and intravenous formulations of Xenleta, or lefamulin, for the treatment of community-acquired bacterial pneumonia, or CABP, in adults. Xenleta is the first IV and oral antibiotic with a novel mechanism of action, approved by the FDA in nearly two decades, the company said. Due to Xenleta novel mechanism of action, the likelihood of developing resistance as well as cross resistance with the beta-lactam, fluoroquinolone, glycopeptide, macrolide, and tetracycline antibiotic classes is low.

  • MarketWatch

    Nabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatment

    Shares of Nabriva Therapeutics PLC shot up 27% to pace the premarket gainers in active trading Tuesday, after the biotechnology company said its new drug application (NDA) for the oral and intravenous formulations of Xenleta, a treatment for community-acquired bacteria pneumonia, was approved by the Food and Drug Administration. Trading volume of over 1.3 million shares was already more than the full-day average of about 922,000 shares. "Today's approval of XENLETA is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and provides a desperately needed IV and oral empiric monotherapy treatment option for adults with CABP," said Chief Executive Ted Schroeder. The company expects Xenleta to be available in mid-September through U.S. specialty distributors, and will have a wholesale acquisition price of $205 per IV patient treatment day and $275 per oral patient treatment day. The stock has slumped 7.5% over the past three months through Monday, while the S&P 500 has gained 2.9%.

  • Benzinga

    The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...

  • FDA approves King of Prussia company's pneumonia drug
    American City Business Journals

    FDA approves King of Prussia company's pneumonia drug

    The company is also planning to resubmit an application for a second new drug candidate that the FDA rejected earlier this year.

  • Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
    Zacks

    Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

    Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

  • Reuters

    UPDATE 2-Nabriva prices two pneumonia antibiotic versions at over $200 per day

    Nabriva Therapeutics Plc on Monday priced an oral and injectable version of its antibiotic Xenleta, which treats community-acquired pneumonia, at more than $200 per day after it received approval from the U.S. Food and Drug Administration. It's the first drug by the company to be approved by the FDA and is expected to launch in mid-September.

  • Benzinga

    The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week

    Biotech stocks succumbed to the broader market weakness, as trade tensions and recession fears shook the broader markets. Earnings and stray clinical readouts triggered some activity in the space. Here ...

  • Benzinga

    Nabriva Shares Volatile As Biopharma Updates FDA Filing Timeline

    Following the receipt of the final minutes of a Type A meeting Nabriva had with the FDA, the company said it expects to resubmit the NDA for injectable Contepo — which is being evaluated for complicated urinary tract infections, including acute pyelonephritis — early in the fourth quarter of 2019. Nabriva's original NDA was accepted by the FDA for priority review Jan. 4, with a PDUFA action date of June 30. The FDA, however, handed down a complete response letter to the NDA April 30, urging the company to address issues related to facility inspections and deficiencies at one of the company's manufacturers.

  • Benzinga

    The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...

  • Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock?

    Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

  • Are Insiders Buying Nabriva Therapeutics plc (NASDAQ:NBRV) Stock?
    Simply Wall St.

    Are Insiders Buying Nabriva Therapeutics plc (NASDAQ:NBRV) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Melinta (MLNT) Announces Preliminary Product Sales for Q2
    Zacks

    Melinta (MLNT) Announces Preliminary Product Sales for Q2

    Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.

  • Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
    Zacks

    Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

    The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.

  • Hedge Funds Have Never Been More Bullish On Nabriva Therapeutics plc (NBRV)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Nabriva Therapeutics plc (NBRV)

    The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

  • Benzinga

    FDA Type A Meetings: What You Need To Know

    ADR (NASDAQ: NBRV) shares traded higher last week after the micro-cap biotech said it requested a Type A meeting with the FDA regarding the complete response letter for the new drug application for its investigational compound Contepo to treat complicated urinary tract infections, including acute kidney infections. The FDA shot down the regulatory application in early May, citing issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers. The FDA and the applicants of regulatory filings interact with each other during the review period regarding advice relating to the development and review of investigational new drugs and biologics.

  • How Many Nabriva Therapeutics plc (NASDAQ:NBRV) Shares Do Institutions Own?
    Simply Wall St.

    How Many Nabriva Therapeutics plc (NASDAQ:NBRV) Shares Do Institutions Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Nabriva Therapeutics plc (NASDAQ:NBRV) should be aware of the most powerful shareho...

  • After FDA rebuff, Nabriva turns its attention to Europe
    American City Business Journals

    After FDA rebuff, Nabriva turns its attention to Europe

    Nabriva is seeking European approval for both intravenous and oral formulations of Lefamulin as a treatment of community-acquired pneumonia in adults.

  • Benzinga

    Nabriva Shares Tumble After FDA Issues CRL For Antibiotic Candidate

    Microcap biotech Nabriva announced Tuesday after the close that it received a complete response letter for its New Drug Application for Contepo injection, chemically fosfomycin, for treating complicated urinary tract infections, or cUTIs, including acute pyelonephritis. Nabriva said the letter pertains to issues related to facility inspections and manufacturing deficiencies at one of its contract manufacturers. Nabriva said it will seek a Type A meeting with the FDA to discuss the findings.

  • Benzinga

    The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...

  • Nabriva fails to win FDA approval for experimental antibiotic
    American City Business Journals

    Nabriva fails to win FDA approval for experimental antibiotic

    The federal agency wants the King of Prussia company to adress facility inspection issues and manufacturing deficiencies at one if its contract manufacturers.